Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Regional airports like Palm Springs International Airlines are trying to expand international offerings after traffic ...

On Thursday, former Vice President Kamala Harris toured the Palisades fire zone with Supervisor Lindsay Horvath, while EPA ...

Beaver Stadium looks drastically different, as the West side's press box and upper seating deck have been removed.

Kura and Kyowa used the announcement to confirm that they are on track to file a new drug approval application with the FDA ...

Jasper’s Downtown Revitalization Phase II Project is moving forward despite recent setbacks caused by last month’s ice storm, according to city officials. Construction teams are working to compensate ...

And with a growing number of companies in the GLP-1 space, investors may be losing interest in the stock. Could Viking's ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.